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Summary
Objective: To investigate whether any of 14 serum and urine molecular markers (MMs) used to monitor osteoarthritis (OA) would be
associated with particular clinical end-points.
Design: Thirty-nine OA patients were bled and urine collected at five time points: at baseline visit and at visits 1, 3, 6 and 12 months later.
Twelve clinical measurements were made and the concentrations of each of 14 MMs were determined. Principal component analysis,
stepwise linear regression with backward elimination, and logistic regression were used to determine the correlations between MMs and
clinical measures.
Results: Principal component analysis was used to reduce the 12 clinical measurements into three independent clinical clusters: baseline
clinical assessments, changes in clinical assessments and signal joint measurements. The 14 MMs were similarly reduced to five MM
clusters. Each of the three clinical clusters was correlated with a single but different MM cluster. Baseline clinical assessments were
correlated with bone markers typified by hydroxylysyl pyridinoline (HP) crosslinks, swelling of the signal joint was correlated with
inflammation markers, especially CRP, and the change in clinical assessments over the 1 year evaluation was correlated with TGF1. There
was no correlation between any of the skeletal markers and the clinical measures, a situation which draws attention to the need for a direct
assessment of cartilage damage in OA to validate the use of cartilage markers.
Conclusions: This study demonstrates statistical methodology for analysis of clinical trials using multiple MMs and clinical end-points. The
patient numbers are sufficient to test hypotheses of relationships of single MMs such as CRP, TGF1 and HP to clinical measures, but larger
clinical trials are needed to validate hypotheses. © 2001 OsteoArthritis Research Society International
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One of the pressing problems in osteoarthritis (OA)
research is the definition of molecular markers (MMs) that
will facilitate determination of patients’ prognosis and need
of treatment. There are a large number of candidate MMs
and we have been exploring the utility of 14 of them1,21.
They have been measured in an archival set of serum,
plasmas and urines from patients in the placebo group
(NSAID-permitted) of a completed clinical trial. It is com-
monly recognized that the concentrations of cartilage
markers in synovial fluid, being closer to their site of origin,
may be better correlated with pathologic changes in carti-
lage metabolism3. Nevertheless, this study focused on
MMs in blood and urine—markers that can be readily
sampled longitudinally and that are amenable to large scale
clinical trials—in anticipation that changes in these markers
might reflect changes in clinical status.224The MMs that we have so far examined can be divided
into skeletal or inflammation markers. Skeletal markers are
related to cartilage or bone metabolism. They are keratan
sulfate (KS)4–6, the C-propeptide of type II procollagen
(CPII)7, bone sialoprotein (BSP)8, cartilage oligomeric
matrix protein (COMP)9,10, cartilage proteoglycan aggre-
can fetal epitope (epitope 846)11,12, and the collagen
cross-links hydroxylysyl pyridinium (HP) and lysyl pyridin-
ium (LP)13–15. Disease markers related to inflammation
that were analysed were C-reactive protein (CRP)16, tumor
necrosis factor receptor type I (TNF-RI) and type II (TNF-
RII), interleukin 6 (IL-6)17, hyaluronan (HA)18–20, TGF121,
and eosinophil cationic protein (ECP)22,23.
In most clinical studies, MMs have been examined one
or two at a time to determine potential relationships to
clinical disease in OA. Our purpose was to simultaneously
examine a series of MMs in blood and urine to determine
any clinical correlations between them and to estimate the
utility of multiple MM measurements. Unfortunately, the
analysis of clinical trials involving many variables is fraught
with the chance occurrence of spurious relationships. A
variety of strategies can be taken to strengthen the chance
of finding meaningful relationships. In this paper, we use a
technique called principal component analysis to reduce
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Patients were selected with Grades I to III OA of the knee
or hip by the ACR OA criteria24,25. Five males and 34
females with mean age 57, range 45–61 and a primary
diagnosis of OA were entered into the study. The knee
(31 patients) or hip (eight patients) as appropriate was
designated the signal joint. The majority of patients had
additional joint involvement. Each patient was removed
from therapy (NSAID) for 1 week prior to the baseline (t=0)
visit. Five milliliters of blood and a 24 h urine specimen
were taken at baseline. After the baseline visit, patients
were placed on piroxicam 20 mg/day, and blood and urine
specimens collected at visits 1, 3, 6, and 12 months later. A
control cohort was also formed consisting of 13 females
and eight males who were without joint pain and with a
mean age of 50 years and an age range of 45–63 years.Patient status was determined at each visit. Two phys-
ician clinical assessments and four patient visual analog
assessments were made at each visit. These measures are
listed in Table I with the range of values allowed for each
measure. Serum and urine were aliquoted and stored at
−72°C until assayed at Pfizer or shipped to other labora-
tories for assay. Patients were required to have serum and
urine taken at all five measurement periods in order to
determine stability and changes in the markers over a
1-year period.Table I
Clinical measures with their range of values*
Disease measurement
(Range of values)
Patient values
geometric mean
Patient values
range
Patient change
geometric mean†
Patient self-assessment of disease activity (1–5) 4 2–5 −2.6
Physician’s global assessment of disease activity (1–5) 3 2–4 −2.2
Pain at rest (1–5) 2 3–17 −1.2
Pain on weight-bearing (0–17) 13 3–17 −5.7
Stiffness (0–17) 10 0–17 −6.8
Soft tissue swelling (0–3) 1 0–3 −0.8
*Clinical parameters were based on the scoring by the physician for the physician global assessment scale,
and soft tissue swelling of the knee. The remainder of the assessments were made by the patients, who globally
rated their disease from mild to severe (patient self-assessment) or rated other parameters of their disease using
visual analog scales.
†Geometric means of changes were calculated as follows: R=log((X+dX)/X).
GeoMean(dX)=GeoMean(X)*exp(Mean(R)); X=clinical measure, dX=change.Methods
Keratan sulfate (KS) and carboxypropeptide of type II
procollagen (CPII) were measured by competitive radio-
immunoassay (RIA). Cartilage oligomeric matrix protein
(COMP), bone sialoprotein (BSP), and aggrecan fetal
epitope (epitope 846) were measured by Elisa. C-reactive
protein (CRP), tumor necrosis factor receptor type I (TNF-
RI), tumor necrosis factor receptor type II (TNF-RII), inter-
leukin 6 (IL-6), transforming growth factor beta 1 (TGF-1),
eosinophil cationic protein (ECP), hyaluronic acid (HA)
were measured by commercial Elisas. Hydroxylysyl pyridi-
noline (HP), lysyl pyridinoline (LP) and creatinine were
analyzed biochemically. Each assay was carried out as
previously detailed2.
Statistical analyses were carried out with SAS (SAS
Institute, Cary, NC) and Statistica (StatSoft Inc, Tulsa, OK)
software. Possible associations in clinical data at baseline
were explored by principal component analysis with
orthomax factor rotation, and by Spearman rank order
correlation. Clinical data were grouped into clusters of
related measures by principal component analysis just as
MM data were grouped into clusters previously2. For all
statistical tests that require normal distributions, the use of
logarithms of all independent variables except age was
necessary. Associations between MM clusters and clinical
measurement clusters were determined by stepwise linear
regression using an open procedure that permitted all
possible associations of MM clusters with each clinical
measurement cluster. A combined addition and elimination
method was used until only statistically significant associ-
ations remained. At each step the most non-significant
variable was eliminated and the regression recomputed.
Each of the variables previously removed as non-
significant was placed back into the linear regression to
ensure that it had not become significant with the removalthe size of the variable sets to be analysed. Simply,
principal component analysis is a method for segmenting a
set of variables into clusters where each cluster is made up
of variables that change in a similar manner. For example,
in a previous paper we found that the 14 MMs could be
divided into five independent clusters of markers. The
power of the technique suggested to us that the set of
clinical variables could be similarly reduced and an optimal
method of finding meaningful data might be through exami-
nation of the correlations between the reduced sets.
A rigorous statistical analysis of the relationship between
MMs and clinical data is necessary in order to identify one
or a set of MMs, the rise and fall of which might reflect
changes in disease activity. Such methods are necessary
for finding relationships among variables such as clinical
measures of disease, patient responses and MMs,
changes which display significant intrinsic variation. Finally,
in working with a finite patient population, results may or
may not represent an adequate sample of the true popu-
lation. Therefore, in seeking a relationship between MMs
and clinical findings, the primary value of an initial appli-
cation of statistical methods to a dataset is to generate
hypotheses that can be tested through further experimen-
tation and examination of additional patient populations. In
this study we used reduced sets of clinical measures and
MMs obtained from principal component analysis to extract
correlations. Those correlations were deconvoluted to
obtain individual single marker correlations with clinical
variables.
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individual MMs with individual clinical measurements, the
regression between the two variables was determined
using a logistic regression model using the equation:
Y={(Ymax−Ymin)/(1+(C50/X)H)}+Ymin
where Y is the clinical value of the parameter, Ymax and
Ymin are respectively the maximum and the minimum
allowable values, X is the concentration of the MM, C50 is
the concentration of the MM at the half point between Ymax
and Ymin, and H is the maximum slope of the sigmoid
curve. Overall statistical significance was computed using
an F-ratio in Statistica. Logistic regression was used
because of the non-continuous truncated nature of the
clinical measures. To follow up the regression, Fisher’s
exact test was used to determine the significance of the
separation of the patients into a 2×2 layout: marker level
greater or less than the C50, and of greater or lesser clinical
severity.ResultsPRINCIPAL COMPONENT ANALYSIS OF THE CLINICAL PARAMETERS
Six measures of clinical disease were determined for
each patient at baseline and at each of four subsequent
visits over a 1-year period. In addition, changes from
baseline were calculated at each subsequent visit for each
of the six clinical measures, resulting in a total of 12 clinical
variables (six status and six change measures). Principal
component analysis was used to reduce the number of
clinical variables. There was a highly significant separation
of the 12 clinical variables into three independent factors.
The principal components of each factor and their levels of
significance are listed in Table II. The principal components
of Factor 1 are measurements for five parameters at
baseline (patient global assessment, physician’s global
assessment, pain on weight-bearing, pain at rest andstiffness). Each measurement is a numerical severity
score. The principal components of Factor 2 are the
changes in status of each of the five parameters in Factor 1
over the 1-year period. The principal components of Factor
3 were measurements in which the signal knee was evalu-
ated at each visit and both the status and changes in that
joint recorded. For clarity in discussing the analysis, the
principal components of the three factors are referred to as
clusters and called respectively: baseline clinical, change in
clinical, and signal joint.Association of markers clusters with clinical clusters
In the related paper2, a principal component analysis
was carried out on 14 MMs in controls (nonOA) and OA
patients in this study. Five factors were found to describe
best the variation of the MMs. Because the principal
components of these five factors were logically segregated,
the principal components of each factor could be given a
descriptive name: inflammation markers, bone markers,
cartilage synthesis markers, cartilage degradation markers,
and TGF. The possibility of a meaningful association
between each of the five MM clusters at baseline and each
of the three clinical clusters going forward was explored by
open stepwise linear regression*. In effect all potential
combinations of the five MM clusters were explored to see
which, if any, sets of markers were correlated with each
clinical cluster. All combinations were tested and the most
non-significant set was removed with a forward/backward
procedure. This process was repeated until only significant
associations remained. For each clinical cluster a signifi-
cant correlation was found with only one MM cluster. The
baseline clinical status was associated with the bone
markers; the change in clinical was associated with TGF1,
and the signal joint measures were associated with theTable II
Clinical measurements at baseline and their change at one year*
Clinical measures Factor 1 Factor 2 Factor 3
Pain on weight-bearing 0.793 −0.187 −0.043
Stiffness 0.756 −0.081 0.077
Patient’s self-assessment of disease activity 0.705 0.023 −0.295
Pain at rest 0.665 −0.242 −0.086
Physician’s assessment of disease activity 0.620 −0.207 0.231
Change in disease—physician’s assessment 0.002 0.813 −0.209
Change in pain on weight-bearing −0.455 0.775 0.116
Change in stiffness −0.318 0.753 −0.135
Change in pain at rest 0.104 0.752 0.393
Change in disease–patient self-assessment −0.293 0.625 0.111
Change in soft tissue swelling—signal joint 0.172 0.211 0.886
Soft tissue swelling—signal joint 0.266 0.151 −0.842
Variance due to factor§ 3.03 3.00 1.89
*Clinical values (see Table I) from each OA patient were utilized to determine the correlation matrix. Change
values were taken between baseline and the 1 year assessment.
†Principal component analysis coefficients. Matrix rotation and determination of the number of factors were
carried out in SAS with the orthomax software and the requirement that the eigenvalues must be greater than one
for significance. Three factors were found.
‡Isolation of independent factors. The primary components in each Factor are shown in bold.
§The three factors together account for 66% of the total variance.*There were no associations between changes in MMs and
clinical status or change variables.
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The bone marker cluster consisted of measurements of
three markers, hydroxylysyl pyridinoline (HP), lysyl pyridi-
noline (LP) and bone sialoprotein (BSP). When the three
markers were examined individually for their association
with baseline clinical, only pyridinoline gave a highly signifi-
cant positive correlation (P<0.001). The logistic regression
parameters for equation 1 (Materials and methods) are
Ymax=4, Ymin=3, C50=5.15, H=8.0; N=34, R=0.668, P<
0.001. Using the mid-point of the logistic regression, aFisher’s exact test gave significance of P=0.0032. To gain
a better understanding of the nature of the correlation, the
values for pyridinoline were examined as a function of age
(Fig. 1). The majority of patients (and controls) fall within
the bounds of 2–6 g HP/cg creatinine. In our series, a
significant number of OA patients over age 53 have values
greater than 6 and the individuals with the highest HP
values (≥6) all had the more severe grade of OA and all but
one were female.Table III
The association of clinical clusters with marker clusters*
Clinical cluster Marker cluster Slope coefficient R2 P-value
Value Std error
Baseline clinical Bone markers 0.653 0.154 0.462 0.0004
Change in clinical TGF1 0.410 0.198 0.170 0.050
Signal joint Inflammation −0.711 0.225 0.321 0.005
*Possible associations between the three clinical clusters and the five marker clusters, individually or
combinations, were explored by univariate stepwise linear regression. In the analysis, the dependent variable
was the selected clinical cluster, and all five marker clusters were initially included as predictor variables.
Non-significant (P>0.05) predictors were removed by a backward/forward stepwise procedure, until only
significant (P≤0.05) marker factor(s) remained.Fig. 1. The correlation of pyridinoline (HP) as nM HP/cg creatinine with age and presence of OA is shown. The linear regression line of
HP/creatinine versus time is shown (solid line) with the 99% confidence bounds (dotted lines). The regression was performed using all
controls (nonOA individuals) and OA patients. Control (nonOA) females (), OA females (), control males (h), OA males (").Change in clinical vs TGF1
A single molecular marker, TGF1, was found to have a
statistical association with the change in clinical cluster
(P<0.5). To gain a better understanding of its relationship to
clinical parameters a further principal component analysis
was conducted. All six clinical variables at baseline, 1, 3, 6,inflammation markers. The associations and the level of
significance are shown in Table III. Neither of the two
cartilage MM clusters (cartilage synthesis cluster or carti-
lage degradation cluster) showed an association with the
clinical marker clusters.
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ponent analysis. Unlike the previous analysis, clinical
assessments of change were omitted from this analysis.
Under this circumstance the clinical variables broke down
into two components. The first was composed of patient-
related variables, patient self-assessment, pain on weight-
bearing and stiffness; the second was composed of
primarily physician-related variables, physician’s global
assessment, soft tissue swelling and pain at rest (Table IV).
The TGF1 association remained with the patient-related
principal component factor 1 (PC-1) (Table IV) and the
association over the year period is given in Fig. 2. When
each individual clinical variable within the patient-related
factor is examined individually, the correlation was strong-
est with the change in patient global assessment from
baseline. The parameters of best fit of patient global
assessment compared with baseline TGF1 are Ymax=0,
Ymin= −2, C50=37.5, H=3.77; N=33, R=0.590, P<0.001.
By principal component analysis we previously found that
TGF1 was independent of the other MMs2. Using the
two cases—change and no change—with the division
point defined by logistic regression as 38 ng/ml of TGF1,
Fisher’s exact test gave significance of P=0.0003.Signal joint vs inflammation markers
The correlations between the signal joint and the change
in signal joint with the Inflammation Markers were exam-
ined next. A significant correlation was found only with the
signal joint at baseline and the inflammation markers
(P<0.005). The relationship between the inflammation
markers and the change in signal joint did not reach
statistical significance. We then explored the signal joint at
baseline with each of the inflammation markers. CRP was
most highly correlated (P<0.01). Of the remaining markers,
only TNF-RI reached statistical significance (P=0.05).Table IV
Clinical measurements at baseline, 24 weeks and 1 year*
Clinical
measure
Baseline Week 24 1 Year
Factor 1 Factor 2 Factor 1 Factor 2 Factor 1 Factor 2
Pain on weight-bearing 0.874 0.156 0.886 0.141 0.858 0.233
Stiffness 0.830 0.056 0.843 0.243 0.832 0.239
Patient’s self-assessment 0.710 0.224 0.742 0.356 0.801 0.199
Soft tissue swelling 0.018 0.786 0.056 0.841 0.047 0.877
Pain at rest 0.136 0.754 0.382 0.733 0.409 0.728
Physician’s assessment 0.407 0.704 0.378 0.723 0.449 0.682
Variance due to factor 2.141 1.760 2.338 1.973 2.441 1.915
*Principal component analysis coefficients and isolation of independent factors.
The primary components in each factor are shown in bold.Discussion
All clinical data obtained at baseline were examined by
principal component analysis to derive independent factors
with which to examine possible correlations with MMs. This
process served two purposes: first, it strengthened the
associations within the clinical data by clustering the
measures into independent categories, and second, by
reducing the number of clinical variables, it decreased the
chances of obtaining spurious correlations. This datasetcontained, as predictor variables, both baseline values and
change values over the entire year. We maintained both
baseline and change values together in this analysis, using
the reasoning that the amount of change could be related
to the initial values at baseline. In additional analysis
(results not shown) the association between TGF1 and
clinical change did not depend on the inclusion of baseline
values as a predictor variable.
The clinical measures were found to cluster into three
logical categories. The first category was composed
of baseline determinations of patients’ global self-
assessment, physicians’ global assessment, stiffness, pain
at rest and pain on weight-bearing. This grouping might
well have been suspected since a patient with a high score
on one of these parameters most probably would have a
high score for the others and vice versa. Similarly, the
segregation of the changes over the year of the same
clinical variables into a related group might also be
expected a priori. Improvements or deteriorations in one of
the measures over the year will frequently be mirrored in all
the related measures. Finally, unlike the other clinical
variables, the signal knee requires a determination of
swelling by direct measurement. It is not a global assess-
ment of general pain, stiffness, well-being, etc. Thus it is not
unexpected that these measurements should segregate
independently from the other two clinical clusters. Since no
marker correlated with the change in swelling of the signal
joint, this association did not enter into the analysis.
The three clusters of clinical parameters were then
examined for associations with the five sets of MMs. With
each clinical cluster relationships were found, but only to a
single MM group. Two groupings, the synthetic and the
degradation markers, failed to show any correlation with
the clinical parameters. Since in OA the change in cartilage
structure over a single year period is normally limited, this
finding suggests that subjective clinical evaluations over a
1-year period do not reflect cartilage changes. These
results emphasize the great importance of obtaining quan-
titative measures of the change in joint structure in order to
determine the utility of these markers.
It was an unexpected finding that there was a correlation
between the clinical condition at baseline and the level of
HP. Since the status at baseline reflects cumulative dam-
age over time, we expected there to be no direct correlation
between any marker and baseline measurements. How-
ever, Thompson et al.26 have reported a correlation of
radiological score and HP levels. Scintigraphy of OA
Osteoarthritis and Cartilage Vol. 9 No. 3 229Fig. 2. Change in the patient-related principal component factor (PC-1) with TGF-1 at 1 month, 6 months and at 1 year. PC-1 is a normalized
and dimensionless factor from principal component analysis that reflects the combined changes in patient self-assessment of disease
activity, physician self-assessment of disease activity, pain at rest, pain on weight-bearing, and stiffness as it changed from baseline to
1 month, 6 months, and 1 year. Only the change at 1 year is significant (P=0.01).patients often shows abnormal bone scans unrelated to the
degree of radiological abnormality27,28. MacFarlane et al.29
and Dieppe et al.30 have suggested a correlation with
progression of OA and bone scintigraphic activity, i.e.
higher bone metabolism will be reflected later in more
severe OA. Sharif et al.31 found that increased synovial
fluid osteocalcin levels were correlated with increased
abnormality of scintigraphic scans. Petersson et al.32 have
found scintigraphic changes associated with joint pain inearly OA. This suggests that, in some patients, bone
metabolic changes may be related to clinical changes
in OA.
The explanation for the association of HP and OA
severity at baseline may be related to a combination of
demographics and changes with menopause. Menopausal
status, unfortunately, was not available in the retrospective
data of this study. A plot of HP vs age in our patient group
shows that after age 50, the population splits into those with
230 I. G. Otterness et al.: Markers for OA: Correlation with clinical measureselevated HP and those who maintain a normal HP. Individ-
uals with low or normal HP were distributed somewhat
evenly between the more and less severe categories.
Interestingly, most of the individuals with highest HP were
in the most severe category. It is this population that
determines the correlation. Moreover, all of those individ-
uals with elevated HP were females. This suggests to us
the hypothesis that, rather than HP being a predictor for OA
severity, those individuals in the high HP loss category may
have additional conditions that contribute to a high clinical
score.
Only a single parameter, TGF1, appeared to be associ-
ated with the change in clinical over the 1-year period. High
TGF1 was strongly associated with a less favorable
outcome. TGF1 has been found in OA synovial fluid33,34.
It causes osteophyte formation when administered intra-
articularly35, and osteophytes are known to be associated
with OA pain. In addition, TGF1 causes increased col-
lagen36 and proteoglycan synthesis37,38, suggestive of
attempted repair. In addition, blockade of TGF1 by anti-
body has a profound inhibitory effect on the pathology of
streptococcal cell wall-induced arthritis39. Thus there are
reasons to believe that the association of higher levels of
TGF1 with a less favorable change in clinical status is not
a spurious association.
The association of joint tenderness and swelling with
CRP is in part a recapitulation of findings previously
made in RA although the degree of inflammation and the
elevation of CRP are much lower in OA than in RA. In our
OA patients, CRP rose three to five-fold to a mean of
5 g/ml, a level that previously was thought to be within the
normal range16. Studies in RA have shown the elevation to
be associated with inflammation in the large joints40 and
our results could reflect similar findings. As neither ESR nor
serum amyloid A (SAA) are elevated in OA, this points to a
more general utility for CRP as an inflammation marker of
arthritic disease.Conclusions
We have applied principal component analysis as a
reductive strategy to analyse a clinical study of 12 clinical
parameters and 14 MMs. This study of 39 patients allows
us to hypothesize a relationship between HP and baseline
clinical status, between CRP and joint swelling, and
between TGF1 and change in clinical status. Because of
the novelty of the associations of HP and TGF1 with
clinical findings, additional confirmatory studies are
needed. Since no correlation was observed with any of the
cartilage markers, this study highlights the need for clinical
measures that reflect the structural integrity of articular
cartilage and its changes during OA.References
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